Ecolab said reported net sales for Q1 2024 were $3,751.9 million, up 5% from $3,571.6 million a year earlier. It said reported diluted EPS was $1.43 and adjusted diluted EPS was $1.34 (+52%).

1. 01

   Ecolab said reported net sales for Q1 2024 were $3,751.9 million, up 5% from $3,571.6 million a year earlier. It said reported diluted EPS was $1.43 and adjusted diluted EPS was $1.34 (+52%).

2. 02

   The company said reported operating income for Q1 2024 was $517.9 million (+47%) and organic operating income margin was 14.7% (+400 basis points). It cited lower delivered product costs, value-based pricing and volume growth as offsetting growth-oriented investments in the business.

3. 03

   Ecolab said cash flow from operating activities for Q1 2024 was $649.4 million. Free cash flow, after deducting capital expenditures of $201.5 million, was $447.9 million, up from $24.5 million a year earlier.

4. 04

   Ecolab said it signed a definitive agreement to sell its global surgical solutions business to Medline for $950 million in cash, and raised its full-year adjusted diluted EPS outlook to $6.40 to $6.70 from the prior $6.10 to $6.50 range.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.